Home|DSIJArticleDetail

Railway Stock with 200 Per cent Multibagger Returns in Just 6 Months: Anti-Collision Device Manufacturer Bags Order Worth Rs 2,041.40 Crore – Both FIIs and DIIs Purchase Stake
Railway Stock with 200 Per cent Multibagger Returns in Just 6 Months: Anti-Collision Device Manufacturer Bags Order Worth Rs 2,041.40 Crore – Both FIIs and DIIs Purchase Stake

Railway Stock with 200 Per cent Multibagger Returns in Just 6 Months: Anti-Collision Device Manufacturer Bags Order Worth Rs 2,041.40 Crore – Both FIIs and DIIs Purchase Stake

The company’s shares have delivered a multibagger return of over 5,150 per cent in the past 5 years.

Rakesh Deshmukh Article rating: 4.2
Mukul Agrawal Holds 5.53 Per cent Stake: Railway Infra Company Secures Order Worth Rs 2,15,59,180 from Rail Coach Factory – Net Profit Surged by 900 Per cent!
Mukul Agrawal Holds 5.53 Per cent Stake: Railway Infra Company Secures Order Worth Rs 2,15,59,180 from Rail Coach Factory – Net Profit Surged by 900 Per cent!

Mukul Agrawal Holds 5.53 Per cent Stake: Railway Infra Company Secures Order Worth Rs 2,15,59,180 from Rail Coach Factory – Net Profit Surged by 900 Per cent!

The company’s shares have delivered an impressive return of over 100 per cent to its shareholders in just 1 year.

Rakesh Deshmukh Article rating: 4.8

In FY24, the company’s net profit surged by 900 per cent YoY from Rs 3 crore to Rs 30 crore.

Mukul Agrawal Holds 5.53 Per cent Stake; Railway Infra Company Secures Order Worth Rs 1,11,01,440 from Integral Coach Factory – Net Profit Surged by 900 Per cent!
Mukul Agrawal Holds 5.53 Per cent Stake; Railway Infra Company Secures Order Worth Rs 1,11,01,440 from Integral Coach Factory – Net Profit Surged by 900 Per cent!

Mukul Agrawal Holds 5.53 Per cent Stake; Railway Infra Company Secures Order Worth Rs 1,11,01,440 from Integral Coach Factory – Net Profit Surged by 900 Per cent!

The company’s shares have delivered an impressive return of around 95 per cent to its shareholders in just 1 year.

Rakesh Deshmukh Article rating: 5.0

DSIJ MINDSHARE

Mkt Commentary20-Dec, 2024

IPO Analysis20-Dec, 2024

Mindshare20-Dec, 2024

IPO Analysis20-Dec, 2024

IPO Analysis20-Dec, 2024

Knowledge

MF15-Nov, 2024

General15-Nov, 2024

MF14-Nov, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual

View Registration Certificate

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual

View Registration Certificate

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP
BASL Membership ID: 1346

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Condition | Privacy Statement | WhiteList